Category: Oncotarget

Oncotarget News

Oncotarget

Oncotarget Welcomes New Editorial Board Members

July 22, 2024

Oncotarget is also offering a 50% discount on publication fees until the end of the year.BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial... read more

Oncotarget

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

July 22, 2024

Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.”BUFFALO, NY-... read more

Oncotarget

DDX41 and Its Unique Contribution to Myeloid Leukemogenesis

July 19, 2024

myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.”BUFFALO, NY- July 19, 2024 – A new editorial paper was... read more

Oncotarget

Using Early On-treatment Circulating Tumor DNA Measurements as Response Assessment in Metastatic Castration Resistant Prostate Cancer

July 17, 2024

results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”BUFFALO,... read more

Oncotarget

HER2-low and HER2-zero in Breast Cancer Between Prognosis, Prediction and Entity

July 16, 2024

we found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer.”BUFFALO, NY- July 16, 2024 – A new editorial paper was published in Oncotarget's Volume... read more

Oncotarget

Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Malignant Pleural Mesothelioma

July 15, 2024

FDG-PET is generally considered as a useful metabolic evaluation tool, while it is also thought to have an emerging role for assessment of systemic therapy response.”BUFFALO, NY- July 15,... read more

Oncotarget

Targeting ABC Transporters in PDAC – Past, Present, or Future?

July 10, 2024

it is crucial for the future application of ABC transporter inhibitors [...] to develop a stratification protocol [...] to identify those PDAC patients who are most likely to benefit from chemosensitization induced... read more

Figure 5: TAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling.

Oncotarget

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers

July 8, 2024

In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.”BUFFALO, NY- July 8, 2024 – A new research paper... read more

Oncotarget

Editorial: Genomics Has More to Reveal

July 2, 2024

If there was any doubt, this discovery demonstrates that genomics, extensively deployed over the past two decades, still has much to reveal to us.”BUFFALO, NY- July 2, 2024 – A... read more

Oncotarget

Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response

June 26, 2024

Depleting amino acid[s] likely expose[s] the Achilles heel of the cancer and exacerbate[s] DNA repair-targeted and immune-based therapy response.”BUFFALO, NY- June 26, 2024 – A new research... read more